Literature DB >> 22801191

Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.

J Krhut1, V Samal, D Nemec, P Zvara.   

Abstract

STUDY
DESIGN: This was a multicentre, prospective, randomised study.
OBJECTIVES: To compare the outcomes of intradetrusor and suburothelial onabotulinumtoxinA injections in patients with spinal cord injury and refractory neurogenic detrusor overactivity (NDO).
SETTING: Urology departments of two tertiary hospitals in the Czech Republic.
METHODS: A total of 32 spinal cord injury patients with severe NDO refractory to the standard anticholinergic treatment were randomised to receive either intradetrusor or suburothelial 300 IU onabotulinumtoxinA injections. Subjective satisfaction, bladder diary data and urodynamic data were compared in both groups before treatment and at 3 months post treatment.
RESULTS: In all, 64.3% patients in the intradetrusor group and 88.8% patients in the suburothelial group were subjectively satisfied with the treatment. There was a significant post-treatment improvement in both groups regarding the number of catheterisations over 24 h, number of incontinence episodes over 24 h, catheterised volume, cystometric capacity, volume at first involuntary detrusor contraction, maximal detrusor pressure during filling and detrusor compliance. No significant differences between the groups were observed, with the exception of improvement of detrusor compliance, which was better in the intradetrusor group. There was one adverse effect comprising transient muscle weakness that was reported by one patient in the intradetrusor group.
CONCLUSION: Results in both groups were comparable. The authors favour suburothelial onabotulinumtoxinA injection because this method allows more precise toxin localisation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801191     DOI: 10.1038/sc.2012.76

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  9 in total

1.  Botulinum Toxin Use in Neurourology.

Authors:  Benoit Peyronnet; Xavier Gamé; Gregory Vurture; Victor W Nitti; Benjamin M Brucker
Journal:  Rev Urol       Date:  2018

Review 2.  The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.

Authors:  Jung Ki Jo; Kyu Nam Kim; Dong Won Kim; Yong Tae Kim; Ji Yoon Kim; Ji Yeon Kim
Journal:  World J Urol       Date:  2017-11-09       Impact factor: 4.226

Review 3.  Botulinum toxin-what urologic uses does the data support?

Authors:  J Seth; M S Khan; P Dasgupta; A Sahai
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

Review 4.  Botulinum toxin for conditions of the female pelvis.

Authors:  Dominique El-Khawand; Salim Wehbe; Kristene Whitmore
Journal:  Int Urogynecol J       Date:  2013-01-24       Impact factor: 2.894

Review 5.  Recent advances in imaging and understanding interstitial cystitis.

Authors:  Pradeep Tyagi; Chan-Hong Moon; Joseph Janicki; Jonathan Kaufman; Michael Chancellor; Naoki Yoshimura; Christopher Chermansky
Journal:  F1000Res       Date:  2018-11-09

6.  Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial.

Authors:  Michał Szczypior; Wojciech Połom; Piotr Wąż; Marcin Matuszewski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-02-06       Impact factor: 1.195

7.  Intravesical Loss of OnabotulinumtoxinA During Endoscopic Intradetrusor Injection - A Multicenter Experience.

Authors:  Vladimír Šámal; Jan Krhut; Vít Paldus; Jana Műllerová; Jan Mečl
Journal:  Int Neurourol J       Date:  2020-03-31       Impact factor: 2.835

8.  The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.

Authors:  Waleed Al Taweel; Khalil Mohammed Alzyoud
Journal:  Urol Ann       Date:  2015 Jul-Sep

Review 9.  Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome.

Authors:  Chun-Hou Liao; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2015-12-28       Impact factor: 2.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.